PMA device
WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery System
Boston Scientific Corp · System, Appendage Closure, Left Atrial (NGV, Class III) · First FDA decision Sep 6, 2023, newest Dec 15, 2025Stroke prevention in atrial fibrillation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
8
Naming "WATCHMAN FLX Pro"
MAUDE reports
3,161
Brand "WATCHMAN FLX Pro", since 2015
PubMed studies
30
Mentioning "WATCHMAN FLX Pro"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
P130013-S079 · Decided Dec 15, 2025 · 123 days after receipt · Normal 180 Day Track No User Fee
Device type: System, appendage closure, left atrial (NGV) · Cardiology
P130013-S078 · Decided Dec 15, 2025 · 123 days after receipt · Normal 180 Day Track No User Fee
Device type: System, appendage closure, left atrial (NGV) · Cardiology
P130013-S059 · Decided Oct 31, 2023 · 41 days after receipt · Normal 180 Day Track No User Fee
Device type: System, appendage closure, left atrial (NGV) · Cardiology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Left Atrial Appendage Closure (LAAC)National determinationOn the books20.34Updated Nov 4, 2026
- Percutaneous Left Atrial Appendage (LAA) Closure TherapyNational analysisReview closedCAG-00445NUpdated Sep 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "WATCHMAN FLX Pro", any status and sponsor, newest update first.
- Combined Pulsed-field Ablation (PFA) and Left Atrial Appendage Occlusion Using Watchman Flx or AmuletPivotal-lookingActive, not recruiting
Prince of Wales Hospital, Shatin, Hong KongAcademic, hospital or other
NCT05560204 · 200 participants (planned) · Start Jan 1, 2023 · Primary completion Dec 31, 2027
Device: Combined Pulsed-field Ablation (PFA) + Left Atrial Appendage Occlusion (LAAO) · For: Combined Pulsed-field Ablation (PFA)
Sites: Jordon, Hong Kong; Hong Kong, Hong Kong; Taipa, Macau
- SIMPLAAFY Clinical TrialPivotal-lookingActive, not recruiting
Boston Scientific CorporationPublic (BSX)
NCT06521463 · 1,857 participants · Start Oct 1, 2024 · Primary completion Jul 7, 2026
Device: WATCHMAN FLX Pro LAAC Device · For: Atrial Fibrillation; Stroke; Bleeding
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 86 sites in all
- OPTION-EMEA Clinical TrialRecruiting
Boston Scientific CorporationPublic (BSX)
NCT07349121 · 500 participants (planned) · Start Jun 18, 2026 · Primary completion Dec 2028
Device: Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional case · For: Atrial Fibrillation (AF); Stroke Prevention in Patients With Atrial Fibrillation; Left Atrial Appendage Closure and 3 more
Sites: Aalst, Belgium; Brussels, Belgium; Zagreb, Croatia · 11 sites in all
5 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "WATCHMAN FLX Pro", and for the whole product code for context.
This brand
3,161 reports: 80 malfunction, 2,747 injury, 334 death
Whole product code NGV
17,771 reports: 1,912 malfunction, 13,990 injury, 1,862 death
Newest reports for this brand
- WATCHMAN FLX? ProInjury
2124215-2026-57534 · Received Oct 29, 2026 · Event dated Oct 21, 2026
Device type: System, Appendage Closure, Left Atrial (NGV)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Low Blood Pressure/ Hypotension; Pericardial Effusion
- WATCHMAN FLX? ProInjury
2124215-2026-57564 · Received Oct 29, 2026 · Event dated Oct 23, 2026
Device type: System, Appendage Closure, Left Atrial (NGV)
Device problem as coded: Migration
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- WATCHMAN FLX? ProInjury
2124215-2026-57570 · Received Oct 29, 2026 · Event dated Oct 26, 2026
Device type: System, Appendage Closure, Left Atrial (NGV)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Thrombosis/Thrombus
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2765-2015 · Started Aug 25, 2015
Reason given: Cross-threading of the hemostasis valve may occur if it is tightened with the dilator in place, possibly preventing subsequent sealing of the valve when desired. This Field Correction reinforces the Directions for Use (DFU) and gives further guidance on correct use of the hemostasis valve to avoid cross-threading and...
Cause as FDA categorized it: Use error · Device type: System, Appendage Closure, Left Atrial (NGV)
Z-2766-2015 · Started Aug 25, 2015
Reason given: Cross-threading of the hemostasis valve may occur if it is tightened with the dilator in place, possibly preventing subsequent sealing of the valve when desired. This Field Correction reinforces the Directions for Use (DFU) and gives further guidance on correct use of the hemostasis valve to avoid cross-threading and...
Cause as FDA categorized it: Use error · Device type: System, Appendage Closure, Left Atrial (NGV)
Published research
The most relevant PubMed records for "WATCHMAN FLX Pro"[tiab]. The summary above synthesizes these.
- Evaluating the New Watchman FLX Pro 40ߙmm Device: A Case Study Series.
Taieb P, Frazzetto M, Teixeira PS, et al. · Catheter Cardiovasc Interv · 2025
- Postimplantation Size of WATCHMAN FLX Pro: A New Left Atrial Appendage Closure System.
Kawaji T, Hojo S, Takahashi R, et al. · Circ Cardiovasc Interv · 2025
- EXPRESS-LAAO protocol with the new WATCHMAN FLX Pro device.
Frazzetto M, Dallan LAP, Texeira PS, et al. · J Invasive Cardiol · 2025
- First-in-human left atrial appendage closure using the WATCHMAN FLX Pro device: a case report.
Nielsen-Kudsk JE, Kramer A, Andersen A, et al. · Eur Heart J Case Rep · 2024Case Reports
- Early device-related thrombosis after WATCHMANࡊ FLX Pro implantation requiring surgical excision in essential thrombocythemia.
Nakatsuji K, Nakajima K, Wakamiya A, et al. · J Cardiol Cases · 2026Case Reports
- Transjugular Access for Left Atrial Appendage Closure.
Hussein A, Ehsan A, Olivares A, et al. · JACC Case Rep · 2025Case Reports
- Bench Test Techniques for the Retrieval of a WATCHMAN FLX Pro With Grasping Instruments.
Fukunaga M, Isotani A, Shirai S, et al. · JACC Cardiovasc Interv · 2025
- Unveiling the endothelialization process of the WATCHMAN FLX Pro: beyond the resolution of conventional imaging.
Kawaji T, Naka M, Yamano S, et al. · Eur Heart J Cardiovasc Imaging · 2026
- More hypoattenuated thickening but better sealing after WATCHMAN FLX Pro: Healing or Thrombosis?
Imamura T · Cardiovasc Revasc Med · 2026Letter
- Giant left atrial appendage closure with the 40 mm watchman FLX pro: overcoming challenging anatomy and transseptal access.
Romano G, Pieri P, Pieri E, et al. · Int J Cardiovasc Imaging · 2026
- Potential of a Novel Large Left Atrial Appendage Closure Device: Short-Term Outcomes of the WATCHMAN FLX Pro 40-mm Versus 35-mm.
Chatani R, Harata H, Fujita M, et al. · Catheter Cardiovasc Interv · 2025
- Combined pulsed field ablation of atrial fibrillation and left atrial appendage occlusion: A single-center experience.
Tabaja C, Mdaihly M, Besir Besir, et al. · Heart Rhythm · 2026
Other devices of this type
Also filed under product code NGV.
- Watchman Left Atrial Appendage (Laa) Closure TechnologyBoston Scientific Corp · PMA 2026
- WATCHMAN FLX Left Atrial Appendage (LAA) Closure TechnologyBoston Scientific Corp · PMA 2025
- Amplatzer Amulet Left Atrial Appendage OccluderAbbott Medical · PMA 2025
- Amplatzer Amulet LAA OccluderAbbott Medical · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.